CN113645972A - 通过atp-竞争性akt抑制剂gdc-0068与e3连接酶配体的接合降解akt及使用方法 - Google Patents
通过atp-竞争性akt抑制剂gdc-0068与e3连接酶配体的接合降解akt及使用方法 Download PDFInfo
- Publication number
- CN113645972A CN113645972A CN202080027366.1A CN202080027366A CN113645972A CN 113645972 A CN113645972 A CN 113645972A CN 202080027366 A CN202080027366 A CN 202080027366A CN 113645972 A CN113645972 A CN 113645972A
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- pharmaceutically acceptable
- akt
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831267P | 2019-04-09 | 2019-04-09 | |
| US62/831,267 | 2019-04-09 | ||
| PCT/US2020/027236 WO2020210337A1 (en) | 2019-04-09 | 2020-04-08 | Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113645972A true CN113645972A (zh) | 2021-11-12 |
Family
ID=72750645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080027366.1A Pending CN113645972A (zh) | 2019-04-09 | 2020-04-08 | 通过atp-竞争性akt抑制剂gdc-0068与e3连接酶配体的接合降解akt及使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12642857B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3952871A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7667742B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113645972A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020270908B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134491A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020210337A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024146599A1 (zh) * | 2023-01-06 | 2024-07-11 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途 |
| WO2025124516A1 (zh) * | 2023-12-14 | 2025-06-19 | 南京正大天晴制药有限公司 | 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114478534B (zh) * | 2020-10-24 | 2025-08-05 | 杭州中美华东制药有限公司 | 具有抗肿瘤活性的嵌合分子及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017197055A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2019173516A1 (en) * | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| IL325256A (en) | 2014-06-13 | 2026-02-01 | Bach Biosciences Llc | FAP-activated medical materials and related uses |
| WO2017185031A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
-
2020
- 2020-04-08 JP JP2021559100A patent/JP7667742B2/ja active Active
- 2020-04-08 EP EP20788177.2A patent/EP3952871A4/en active Pending
- 2020-04-08 US US17/601,640 patent/US12642857B2/en active Active
- 2020-04-08 CN CN202080027366.1A patent/CN113645972A/zh active Pending
- 2020-04-08 WO PCT/US2020/027236 patent/WO2020210337A1/en not_active Ceased
- 2020-04-08 AU AU2020270908A patent/AU2020270908B2/en active Active
- 2020-04-08 CA CA3134491A patent/CA3134491A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017197055A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109562107A (zh) * | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| WO2019173516A1 (en) * | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
Non-Patent Citations (1)
| Title |
|---|
| PHILIPP OTTIS等: "Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy", 《ACS CHEMICAL BIOLOGY》, no. 12, pages 892 - 898 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024146599A1 (zh) * | 2023-01-06 | 2024-07-11 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途 |
| WO2025124516A1 (zh) * | 2023-12-14 | 2025-06-19 | 南京正大天晴制药有限公司 | 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3952871A4 (en) | 2023-06-07 |
| US20220226481A1 (en) | 2022-07-21 |
| US12642857B2 (en) | 2026-06-02 |
| JP7667742B2 (ja) | 2025-04-23 |
| CA3134491A1 (en) | 2020-10-15 |
| AU2020270908A1 (en) | 2021-09-16 |
| AU2020270908B2 (en) | 2025-09-25 |
| WO2020210337A1 (en) | 2020-10-15 |
| JP2022526979A (ja) | 2022-05-27 |
| EP3952871A1 (en) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116249683B (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
| JP7709378B2 (ja) | Heliosの低分子分解誘導剤および使用方法 | |
| EP4034132B1 (en) | Erk5 degraders as therapeutics in cancer and inflammatory diseases | |
| CN116514846A (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
| CN116157400B (zh) | 杂环类衍生物及其制备方法和用途 | |
| CN112638380A (zh) | 小脑蛋白(crbn)配体 | |
| US20230158157A1 (en) | Potent and selective degraders of alk | |
| CN113164475A (zh) | Dyrk1a的大环抑制剂 | |
| JP7626721B2 (ja) | 小分子標的ブロモ/アセチルタンパク質およびその使用 | |
| EP3813834A1 (en) | New crbn modulators | |
| CN116157401B (zh) | 杂环类衍生物及其制备方法和用途 | |
| CN116113416B (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| CN117396208A (zh) | 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法 | |
| JP7667742B2 (ja) | Atp競合性akt阻害剤gdc-0068とe3リガーゼリガンドとの結合によるaktの分解および使用方法 | |
| CN113747894B (zh) | 成纤维细胞生长因子受体2(fgfr2)的降解剂 | |
| CN118695863A (zh) | 靶向swi/snf相关的基质关联的肌动蛋白依赖性染色质调控因子亚家族a成员4(smarca4) | |
| CN104876914B (zh) | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 | |
| CN118119611A (zh) | 用于降解dot1l的小分子及其用途 | |
| CN116801878A (zh) | Her2的有效和选择性抑制剂 | |
| US12162876B2 (en) | Indazole kinase inhibitor and use thereof | |
| CN106146525A (zh) | 三并环类间变性淋巴瘤激酶抑制剂 | |
| CN118772113A (zh) | 作为DNA聚合酶Theta抑制剂的含氮杂环化合物 | |
| BR112019021703B1 (pt) | Compostos heteroaromáticos, composição farmacêutica e uso destes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: Massachusetts, USA Applicant after: Dana Faber Cancer Institute Applicant after: BETH ISRAEL DEACONESS MEDICAL CENTER Address before: Massachusetts, USA Applicant before: DANA-FARBER CANCER INSTITUTE, Inc. Country or region before: U.S.A. Applicant before: BETH ISRAEL DEACONESS MEDICAL CENTER |
|
| CB02 | Change of applicant information |